Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles

Open Access

Original Research

Natl J Med Res. 2016; 6(1): 38-41

A Study to Evaluate and Compare the Efficacy and Safety of Topical Cyclosporine A 0.5% with Topical Placebo (Artificial Tears) in Alleviating the Principal Signs Associated with Vernal Keratoconjunctivitis

Abha Gahlot, Rupali Maheshgauri, Bhargav Kotadia, Kanisha Jethwa, Gira Raninga.

Vernal keratoconjunctivitis is a severe, typically seasonal recurrent ocular inflammatory disorder .Topical cyclosporine-A is inhibitory to many T-cell dependent inflammatory mechanisms which are likely to play role in treatment of vernal keratoconjunctivitis.
The study was conducted on 100 patients of vernal keratoconjunctivits selected from Ophthalmology out patients Department of Dr. D.Y Patil Hospital, Pune. Patients were divided in two groups of 50 each, group I and group II. It was double masked comparison study to assess and compare the efficacy of 0.5% topical Cyclosporine-A and topical placebo in the treatment of vernal keratoconjunctivits.
Comparing therapeutic response of symptoms in two groups at day 28 of the study shows topical cyclosporine was better and favored over placebo.
Patients showed improvement in following symptoms accordingly:
Itching: 49 in group I, 33 in group II.
Discharge: 33 in group I, 4 in group II.
Photophobia: 32 in group I, 1 in group II.
Foreign body sensation: 35 group I, 11 in group II.
Patients showed improvement in following signs accordingly:
Conjunctival inflammation: 40 in group I, 11 in group II.
Papillary hypertrophy: 15 in group I, none in group II.
Limbal changes: 7 in group I, none in group II.

The use of topical cyclosporine for treatment of vernal keratoconjunctivitis should be encouraged to prevent complications associated with the natural course of the disease and prolonged topical use of corticosteroids.

Keywords: vernal keratoconjunctivitis, cyclosporine-A, papillary hypertrophy, limbal changes, itching

Key words: Vernal keratoconjuntivitis, cyclosporine-A, papillary hypertrophy, limbal changes, itching

Similar Articles

Dendritic spine density changes and homeostatic synaptic scaling: a meta-analysis of animal studies.
Moulin TC, Rayêe D, Schiöth HB
Neural regeneration research. 2022; 17(1): 20-24

Computational Modeling of Glycan Processing in the Golgi for Investigating Changes in the Arrangements of Biosynthetic Enzymes.
West B, Wood AJ, Ungar D
Methods in molecular biology (Clifton, N.J.). 2022; 2370(): 209-222

Lesion-induced changes of brevican expression in the perineuronal net of the superior vestibular nucleus.
Magyar A, Racz E, Matesz C, Wolf E, Kiss P, Gaal B
Neural regeneration research. 2022; 17(3): 649-654

Assessment of structural brain changes in patients with type 2 diabetes mellitus using the MRI-based brain atrophy and lesion index.
Zhao H, Wang F, Luo GH, Lei H, Peng F, Ren QP, Chen W, Wu YF, Yin LC, Liu JC, Pan SN
Neural regeneration research. 2022; 17(3): 618-624

Morphometric changes in the cortex following acute mild traumatic brain injury.
Li MJ, Huang SH, Huang CX, Liu J
Neural regeneration research. 2022; 17(3): 587-593

Full-text options

Latest Statistics about COVID-19
• pubstat.org

Add your Article(s) to Indexes
• citeindex.org

Covid-19 Trends and Statistics
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.

ScopeMed Web Sites